Patisiran therapy induced a reduction in TTR serum levels of more than 80%, and an improvement in polyneuropathy and overall quality of life in this cohort of patients, consistent with the results previously conducted in non-transplanted patients on which the efficacy and safety of these molecules were studied and observed [74,75]. The gene discussed is TTR; the disease is polyneuropathy.